You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石药集团(01093.HK)新型靶点抗肿瘤药物“SYHA1801”获临床许可
格隆汇 08-21 18:06

格隆汇8月21日丨石药集团(01093.HK)发布公告,集团附属公司石药集团中奇制药技术(石家庄)有限公司开发的“SYHA1801”已获得国家药品监督管理局批准可以在中国开展临床研究。

该产品在国内外有多件专利申请。该产品是一种新型小分子激酶抑制剂,目前全球尚无同类产品上市,可开发的适应症为晚期实体瘤。临床前研究显示,该产品具有优异的体内外抗肿瘤活性和良好的安全性,极有希望在临床研究中展现出良好的抗癌治疗效果。

基于良好的非临床研究结果,集团将全力以赴推进该产品的临床研究工作,力争该产品尽快上市,以造福全球患者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account